18180 Integrated Myeloma Management for Transplant-Eligible Patients: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT
This PeerView activity, based on a recent live symposium held at the 2018 BMT Tandem Meetings, offers expert insights on the continued integration of next-generation and novel therapeutics in conjunction with the use of autologous hematopoietic stem cell transplant (HCT), while also exploring the clinical implications of new data for the selection of newer induction, post-HCT maintenance, and salvage regimens across the breadth of myeloma treatment settings. Our panel of myeloma experts also assess other issues in transplant-eligible myeloma patients, including early versus late HCT, the growing importance of minimal residual disease (MRD) assessment, and the emergence of new agent classes and therapeutic concepts for heavily pretreated individuals, including those who have had HCT as part of their treatment history.
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists and BMT nurse specialists, and other clinicians involved in the care of patients undergoing HCT.
- Summarize evidence regarding the current role and clinical criteria for the use of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma
- Develop personalized induction and post–ASCT maintenance/consolidation regimens with novel components for eligible patients with multiple myeloma
- Select novel therapeutics for the management of relapsed multiple myeloma post-ASCT
Paul Richardson, MD
RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader, Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Faith E. Davies, MBBCh, MRCP, MR, FRCPath
Professor of Medicine
University of Arkansas for Medical Sciences
Little Rock, Arkansas
All persons in control of content have no relevant financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.